Filing Flows › Ensysce Biosciences (ENSC) › Q1 2026 › vs Q1 2025
Ensysce Biosciences (ENSC) Q1 2026 vs Q1 2025 (year over year)
Ensysce Biosciences's revenue fell $359K (-27%) from $1.3M in Q1 2025 to $961K in Q1 2026.
Ensysce Biosciences, Q1 2026: revenue $961K (-27% year over year), operating margin -370.7%, net loss $3.6M, operating cash flow −$3.5M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $961K | $1.3M | −$359K | -27% |
| Other income, net | $6K | $22K | −$16K | -73% |
| Net loss | $3.6M | $1.9M | $1.6M | +83% |
| Costs & expenses | $4.5M | $3.3M | $1.2M | +38% |
| Operating costs | $4.5M | $3.3M | $1.2M | +38% |
| Research & development | $3.3M | $1.9M | $1.5M | +78% |
| General & admin | $1.2M | $1.4M | −$225K | -16% |
| Operating cash sources | $3.6M | $1.9M | $1.6M | +83% |
| Depreciation | $7K | $0 | $7K | — |
| Share-based compensation | $9K | $16K | −$8K | -46% |
| Working capital & other | $40K | $222K | −$182K | -82% |
| Cash used in operations | $3.5M | $1.7M | $1.8M | +105% |
| Net loss absorbed | $3.6M | $1.9M | $1.6M | +83% |
Questions
How much did Ensysce Biosciences's revenue grow year over year in Q1 2026?
Ensysce Biosciences's revenue fell $359K (-27%) from $1.3M in Q1 2025 to $961K in Q1 2026.